Compare BIO-TECHNE Corp (TECH) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Exxon Mobil Corporation — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Exxon Mobil Corporation trades at $159.75 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 56.4× BIO-TECHNE Corp's market cap, and Exxon Mobil Corporation pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| TECH | XOM | |
|---|---|---|
Market Cap | $11.24B | $634.34B |
Sector | Health | Energy |
52-Week High | $72.29 | $171.52 |
52-Week Low | $43.31 | $105.83 |
Enterprise Value | $11.32B | $673.57B |
Dividend Yield | 0.44% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
ExxonMobil (XOM) trades at $152.94, down 1.22% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue declined to $323.91B in 2025, with net income at $28.84B, while the P/E ratio stands at 25.76. Recent news highlights Exxon's Permian Basin advantages and warnings of potential oil price spikes to $160 per barrel amid Middle East tensions.
Outlook is mixed: strong cash flow and low breakeven costs support dividends, but falling profit margins and net cash outflows pose risks. Analyst consensus is a buy with a $163.71 price target, though geopolitical volatility and energy transition pressures remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
